Cardiac thrombolysis stands as a pivotal medical strategy designed to dissolve blood clots within the coronary arteries, essential vessels responsible for nourishing the heart muscle with oxygen and nutrients. This intervention is frequently employed in addressing acute myocardial infarction, commonly known as a heart attack. In the critical moments of a heart attack, blood clots can impede blood flow to a segment of the heart, inducing tissue damage and potential life-threatening complications. The process of cardiac thrombolysis entails the administration of thrombolytic agents—powerful clot-dissolving medications—to disintegrate the clot and reinstate blood flow to the affected region of the heart. The timely application of this intervention is paramount in minimizing myocardial damage and enhancing the prospects of a positive patient outcome. It is important to note that while cardiac thrombolysis has demonstrated efficacy in specific cases, its suitability is contingent on various factors, including the elapsed time since symptom onset and the overall health status of the patient. Decisions regarding this treatment approach should be carefully weighed by healthcare professionals based on individual patient considerations.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt